- Report
- March 2024
- 199 Pages
Global
From €3243EUR$3,374USD£2,781GBP
€3603EUR$3,749USD£3,090GBP
- Report
- February 2024
- 175 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Report
- November 2023
- 148 Pages
Global
From €4277EUR$4,450USD£3,668GBP
- Report
- November 2018
- 36 Pages
Global
From €6151EUR$6,400USD£5,275GBP
- Report
- February 2024
- 180 Pages
Global
From €5285EUR$5,499USD£4,532GBP
- Book
- April 2020
- 336 Pages
- Book
- June 2012
- 596 Pages
- Book
- April 2023
North America
Systemic Sclerosis (SSc) is a rare autoimmune disorder that affects the skin, joints, and internal organs. It is characterized by thickening and hardening of the skin, as well as inflammation of the blood vessels. In the context of Allergy and Immunology, SSc is a chronic, progressive disorder that is caused by an abnormal immune response. It is associated with an increased risk of pulmonary hypertension, pulmonary fibrosis, and other complications. Treatment options for SSc include immunosuppressants, biologics, and physical therapy.
The SSc market is a growing segment of the Allergy and Immunology market, with a focus on developing treatments that can improve patient outcomes. Companies in this market include AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Novartis, Pfizer, and Sanofi. Show Less Read more